FindTrial
Sign In

GEM

BEHAVIORAL5 trials

Sponsors

University of Virginia, NYU Langone Health, Shi Yanxia, Halozyme Therapeutics, University of Colorado, Denver

Conditions

Breast CancerBreast Cancer ModelCholangiocarcinoma Non-resectableCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticDiabetes Mellitus, Type 2Effects of ChemotherapyGallbladder Adenocarcinoma

Phase 1

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
TerminatedNCT03267940
Halozyme TherapeuticsCholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Non-resectable +1
Start: 2017-10-02End: 2019-11-11Updated: 2020-02-07

Phase 3

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
NCT03006614
Shi YanxiaBreast Cancer, Breast Cancer Model, Effects of Chemotherapy
Start: 2016-04-30End: 2023-03-31Target: 320Updated: 2017-01-16

Unknown Phase

Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations
CompletedNCT02432391
University of VirginiaDiabetes Mellitus, Type 2
Start: 2013-05-31End: 2015-01-31Updated: 2015-05-04
The GEM (Goals for Eating and Moving) Study
CompletedNCT03006328
NYU Langone HealthObesity, Weight Gain
Start: 2017-11-20End: 2022-02-22Updated: 2023-04-27
CGM Plus GEM in Prediabetes
CompletedNCT05580978
University of Colorado, DenverPreDiabetes
Start: 2022-11-01End: 2025-01-15Updated: 2025-02-03

Related Papers

Racial and weight discrimination associations with pain intensity and pain interference in an ethnically diverse sample of adults with obesity: a baseline analysis of the clustered randomized-controlled clinical trial the goals for eating and moving (GEM) study
BMC Public Health2021-12-0113 citations
Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).
Journal of Clinical Oncology2019-01-29
A technology-assisted health coaching intervention vs. enhanced usual care for Primary Care-Based Obesity Treatment: a randomized controlled trial
BMC Obesity2019-01-0922 citations
Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease.
2018-12-189 citations
Abstract 2740: PEGylated recombinant hyaluronidase PH20 (pegvorhyaluronidase alfa PEGPH20) converts HA-rich tumors from resistant to sensitive to anti-PD-L1 immunotherapy in murine syngeneic breast cancer models
Cancer Research2018-07-012 citations
HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.
Journal of Clinical Oncology2018-02-012 citations